Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full regulatory clearance from France's National Agency for Medicines and Health Products Safety (ANSM) for its global pivotal PARADIGM Trial, paving the way for patient recruitment to begin at leading French cardiac centres.
This is a key milestone in Anteris' clinical and regulatory strategy for its DurAVR® Transcatheter Heart Valve (THV), expanding the study's footprint in Europe and supporting efforts to generate the data required for future regulatory submissions.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China.
Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China market, LENZ said. The New Drug Application for LNZ100 in China was submitted in September 2025, with approval anticipated in the first quarter of 2027.
Ocean Power Technologies Inc (NYSE-A:OPTT) has reported successful power generation from its MERROWS-equipped PowerBuoy system deployed off the coast of San Diego in support of US Coast Guard maritime domain awareness operations.
The system has generated close to 0.5MWh of energy to date and has maintained operational performance in an active maritime environment.
American Resources Corp (NASDAQ:AREC) said Monday that ReElement Technologies Corporation, an affiliated minority holding of the company, has been invited to speak at the U.S. Chamber of Commerce's Critical Minerals Summit in Washington, DC on June 11.
Ben Kincaid, CEO of ReElement Africa, will represent the company at the event, held at the Chamber's Great Hall, and will be available for one-on-one meetings.
EnWave Corp (TSX-V:ENW, OTC:NWVCF, FRA:E4U) has entered into a technology evaluation and license option agreement with Swiss Cannabis Selection AG, a Switzerland-based medical cannabis company, to evaluate its Radiant Energy Vacuum dehydration technology for potential use across cannabinoid and botanical products.
Swiss Cannabis Selection, known as SCS, is collaborating with Swiss phytopharmaceutical company Schibano Pharma AG on the evaluation program, which is expected to begin in the coming months.
Reconnaissance Energy Africa Ltd (TSX-V:RECO, OTCQX:RECAF, FRA:0XD) and partners NAMCOR and BW Energy have started production testing operations at the Kavango West 1X well in Namibia, marking what the company calls the first cased production test in the country.
The test will evaluate six zones totalling 420 metres of hydrocarbon-bearing rock across two formations.
Thistle Resources (TSX-V:TRCG) has begun trading on the OTC Pink Market in the United States under the symbol "TRCGF,” the Canadian junior miner said Monday.
The firm will trade on the OTC Pink Market while it awaits final approval to list on the OTCQB Venture Market.
Medicus Pharma (NASDAQ:MDCX) has filed a substantial modification application through the European Union Clinical Trials Information System to advance a Phase 2b study of its prostate cancer treatment Teverelix, the company said on Monday.
The planned trial will focus on patients with advanced prostate cancer and elevated cardiovascular risk who require androgen deprivation therapy (ADT), a segment the company estimates represents roughly $4 billion in annual market opportunity across major pharmaceutical markets.
Grey Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0) has closed the first tranche of its non-brokered private placement, raising gross proceeds of C$500,000 through the sale of 1,250,000 units at C$0.40 per unit.
Company insiders participated in the first tranche for C$184,000, which Grey Matters said did not exceed 25% of the company's market capitalization.
Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF) shares surged 17% to 0.027p after the company reported a key milestone in the restart of operations at its Zulu lithium and tantalum project in Zimbabwe.
The mining group said ore from the run-of-mine stockpile is now being fed through the newly installed flotation plant, marking the latest step in efforts to bring the project back into production.
Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) said it is preparing its largest Zambia drilling programme to date as it looks to convert the Target A1 silver oxide discovery at Mushima North into a maiden JORC Mineral Resource Estimate by the end of the year.
The AIM-listed explorer plans around 4,000 metres of reverse circulation drilling, with work expected to start within the next two weeks. All drill-related permitting is in place, a drilling contract has been signed with Ox Drilling, and access road and drill pad preparation is already underway.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has expanded its scientific network in Alzheimer’s and Parkinson’s disease, adding three senior specialists to its advisory board and launching new Parkinson’s research collaborations.
The neuroscience imaging and biomarker analytics group said Professor Jeffrey Cummings and Professor Charles DeCarli have joined as Alzheimer’s disease advisers, while Professor Stéphane Lehéricy has joined in the field of Parkinson’s disease.